Effects of X Box Kinect 360 in Alzheimer's Disease (AD Alzheimer')
23 juni 2026 uppdaterad av: Ziauddin University
Effect of 3D Kinect Games With Google Cardboard on Motor Control, Cognition, and Quality of Life in Mild to Moderate Alzheimer's Patient
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia that accounting for 60% to 80% of all cases (Better, et al., 2023).
According to world health organization (WHO), more than 55 million people globally live with dementia, and this number is expected to rise to 78 million by 2023 and 139 million by 2050 (WHO, 2021).
Studieöversikt
Status
Har inte rekryterat ännu
Betingelser
Intervention / Behandling
Detaljerad beskrivning
In the line with global epidemiology trend, the prevalence of AD is also rising at the regional level.
In the United States, approximately 6.2 million individual aged 65 and older recently living with AD, and this figured is expected to reach 13.8 million by 2060 (Doher et al., 2023).
Similarly, in Europe, the prevalence of AD is estimated at 5.05%, with a notably higher incidence in women (7.13%) as compared to men (3.31%) (Niu et al., 2017).
Moreover, Asia alone has a higher prevalence of dementia patients than both America and Europe.
A study conducted in tertiary care centers in Karachi showed that 63% of dementia patients had AD (Siddiqui et al., 2018).
Studietyp
Interventionell
Inskrivning (Beräknad)
38
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Silvia Peter William, Mphil
- Telefonnummer: 5 021-36629251
- E-post: williamsilviapeter@gmail.com
Studieorter
-
-
Sindhi
-
Karachi, Sindhi, Pakistan
- Ziauddin University
-
Kontakt:
- Silvia Peter William, Mphil
- Telefonnummer: 5 021-36629251
- E-post: williamsilviapeter@gmail.com
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria
- Alzheimer's disease of age between 50-85 years.
- Diagnosed AD stage Mild to Moderate.
Exclusion Criteria:
- Undiagnosed AD patients.
- Mental or neurological conditions like schizophrenia, Parkinson's, or stroke.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Arms 1
Arm Description: Game-Based Rehabilitation received total 30sessions, 30 minutes/session, 5 times/week for total 6 weeks.
|
Experimental group will receive X boc kinect 360 bomb such as match makers, traffic control, mouse mayhem, strike a pose, pizza catch, flag frenzy, follow the arrow for 30 minutes for five days a week, for six weeks.
|
|
Placebo-jämförare: Arm 2
Arm Description: Conventional Rehabilitation received total 30 sessions, 30 minutes/session, 5 times/week for total 6 weeks.
|
The intervention will run for 30 minutes (excluding rest period), five days a week, for six weeks (Deng, et al., 2025).
The patients will take 1-2 minutes rest after 5 minutes of activity.
Rest periods of 1-2 minutes after every 5 minutes of activity.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Cognition
Tidsram: Baseline
|
Cognitive function will be assessed through among mild to moderate AD patients where low values indicate decrease in cognitive ability.
|
Baseline
|
|
Cognition
Tidsram: After 6 week of Intervention
|
Cognitive function will be assessed through Mini- Cog among Mild to Moderate AD patients where low values indicate decrease cognitive function
|
After 6 week of Intervention
|
|
Motor Function
Tidsram: Baseline
|
Motor function will be assessed using the Timed Up and Go (TUG) Test among patients with mild to moderate Alzheimer's disease (AD), where higher scores (longer completion times) indicate poorer functional mobility
|
Baseline
|
|
Motor Function
Tidsram: After 6 week of intervention
|
Motor function will be assessed using the Timed Up and Go (TUG) Test among patients with mild to moderate Alzheimer's disease (AD), where higher scores (longer completion times) indicate functional mobility
|
After 6 week of intervention
|
|
Quality of Life (QOL)
Tidsram: Baseline
|
Quality of life will be assessed using the Quality of Life in Alzheimer's Disease (QOL-AD) scale among patients with mild to moderate Alzheimer's disease.
Lower scores indicate poorer quality of life, whereas higher scores indicate better perceived quality of life.
|
Baseline
|
|
Quality Of Life (QOL)
Tidsram: After 6 weeks of Intervention
|
Quality of life will be assessed using the Quality of Life in Alzheimer's Disease (QOL-AD) scale among patients with mild to moderate Alzheimer's disease.
Lower scores indicate poorer quality of life, whereas higher scores indicate better perceived quality of life.
|
After 6 weeks of Intervention
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Silvia Peter William, MPhil, Ziauddin University, Karachi, Sindh, Pakistan
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Allmänna publikationer
- Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003 Oct;51(10):1451-4. doi: 10.1046/j.1532-5415.2003.51465.x.
- Cox KL, Clare L, Cyarto EV, Ellis KA, Etherton-Beer C, Southam J, Ames D, Flicker L, Almeida OP, LoGiudice D, Liew D, Vlaskovsky P, Lautenschlager NT. A Randomized Controlled Trial on the Effects of a 6-Month Home-Based Physical Activity Program with Individual Goal-Setting and Volunteer Mentors on Physical Activity, Adherence, and Physical Fitness in Inactive Older Adults at Risk of Cognitive Decline: The INDIGO Study. J Alzheimers Dis. 2021;84(1):207-226. doi: 10.3233/JAD-210479.
- Cousi C, Igier V, Quintard B. French cross-cultural adaptation and validation of the Quality of Life-Alzheimer's Disease scale in Nursing Homes (QOL-AD NH). Health Qual Life Outcomes. 2021 Sep 15;19(1):219. doi: 10.1186/s12955-021-01853-2.
- Conti Filho CE, Loss LB, Marcolongo-Pereira C, Rossoni Junior JV, Barcelos RM, Chiarelli-Neto O, da Silva BS, Passamani Ambrosio R, Castro FCAQ, Teixeira SF, Mezzomo NJ. Advances in Alzheimer's disease's pharmacological treatment. Front Pharmacol. 2023 Jan 26;14:1101452. doi: 10.3389/fphar.2023.1101452. eCollection 2023.
- Chen C, Homma A, Mok VC, Krishnamoorthy E, Alladi S, Meguro K, Abe K, Dominguez J, Marasigan S, Kandiah N, Kim SY, Lee DY, De Silva HA, Yang YH, Pai MC, Senanarong V, Dash A. Alzheimer's disease with cerebrovascular disease: current status in the Asia-Pacific region. J Intern Med. 2016 Oct;280(4):359-74. doi: 10.1111/joim.12495. Epub 2016 Mar 16.
- Cezar NOC, Ansai JH, de Andrade LP. Home-based multimodal exercise program in older people with Alzheimer disease: Randomized controlled trial protocol. Physiother Res Int. 2021 Apr;26(2):e1899. doi: 10.1002/pri.1899. Epub 2021 Feb 15.
- 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023 Apr;19(4):1598-1695. doi: 10.1002/alz.13016. Epub 2023 Mar 14.
- Appel L, Kisonas E, Appel E, Klein J, Bartlett D, Rosenberg J, Smith C. Introducing virtual reality therapy for inpatients with dementia admitted to an acute care hospital: learnings from a pilot to pave the way to a randomized controlled trial. Pilot Feasibility Stud. 2020 Oct 31;6(1):166. doi: 10.1186/s40814-020-00708-9.
- Ries JD, Hutson J, Maralit LA, Brown MB. Group Balance Training Specifically Designed for Individuals With Alzheimer Disease: Impact on Berg Balance Scale, Timed Up and Go, Gait Speed, and Mini-Mental Status Examination. J Geriatr Phys Ther. 2015 Oct-Dec;38(4):183-93. doi: 10.1519/JPT.0000000000000030.
- Amjad I, Toor H, Niazi IK, Pervaiz S, Jochumsen M, Shafique M, Haavik H, Ahmed T. Xbox 360 Kinect Cognitive Games Improve Slowness, Complexity of EEG, and Cognitive Functions in Subjects with Mild Cognitive Impairment: A Randomized Control Trial. Games Health J. 2019 Apr;8(2):144-152. doi: 10.1089/g4h.2018.0029. Epub 2018 Sep 21.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
24 juni 2026
Primärt slutförande (Beräknad)
15 juli 2026
Avslutad studie (Beräknad)
15 augusti 2026
Studieregistreringsdatum
Först inskickad
23 juni 2026
Först inskickad som uppfyllde QC-kriterierna
23 juni 2026
Första postat (Faktisk)
29 juni 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
29 juni 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
23 juni 2026
Senast verifierad
1 juni 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 11691225SPREH (Annan identifierare: Ziauddin University)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .